Artiva Biotherapeutics Inc. (Ticker: ARTV) is a biotechnology company specializing in the development of allogeneic natural killer (NK) cell therapies for autoimmune diseases and cancer. Artiva will list on NASDAQ on July 19, 2024. The company plans to offer 8.7 million shares at a price range of $14.00 to $16.00 per share. The underwriters for the offering are Jefferies LLC, Cantor Fitzgerald & Co, and TD Securities.

The funds raised will be used to advance clinical trials for Artiva's lead NK cell therapy, AlloNK, which is currently in a phase 1 lupus nephritis trial and a separate basket study for multiple autoimmune indications.